Lupin Digital Health, India’s leading cardiac digital-therapeutics company, has launched VITALYFE™, an AI-driven cardiometabolic wellness platform aimed at helping working professionals improve their heart health.

Built on LYFE, India’s first CDSCO-approved Class C software medical device for cardiac conditions, VITALYFE™ extends hospital-grade cardiac care into the preventive wellness space.

Addressing India’s growing cardiometabolic crisis, Lupin noted that up to 80% of corporate employees show early signs of hypertension and dyslipidemia — key risk factors for heart disease. The platform uses AI, behavioral science, and computer vision to detect early risks and deliver personalized, non-medical interventions to reverse heart aging.

“Cardiometabolic risks silently erode both health and productivity,” said Rajeev Sibal, President – India Region Formulations, Lupin. “With VITALYFE, we’re enabling insurers and employers to pair clinical expertise with AI technology for measurable wellness outcomes.”

Available through insurers, brokers, and employers, VITALYFE™ integrates cardiometabolic wellness into employee health programs — enhancing productivity and reducing lifestyle-related health claims.

Sidharth Srinivasan, CEO of Lupin Digital Health, added, “With VITALYFE, we’re extending our evidence-based digital therapeutics to a broader audience — helping professionals understand their heart age and make their hearts younger. Our goal is to make cardiometabolic wellness both measurable and mainstream.”